Akouos Inc logo

AKUS - Akouos Inc Share Price

$22.3 0.1  0.2%

Last Trade - 10/07/20

Sector
Healthcare
Size
Mid Cap
Market Cap £573.4m
Enterprise Value £478.4m
Revenue £n/a
Position in Universe 2541st / 6345
Bullish
Bearish
Unlock AKUS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -7.60%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Akouos Inc revenues was not reported. Net loss increased 77% to $10.4M. Higher net loss reflects Research and development increase from $3.1M to $8M (expense), General and administrative - Balancing increase from $622K to $2.4M (expense), Stock-based Compensation in SGA increase from $9K to $57K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.18 to -$0.32.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AKUS Revenue Unlock AKUS Revenue

Net Income

AKUS Net Income Unlock AKUS Revenue

Normalised EPS

AKUS Normalised EPS Unlock AKUS Revenue

PE Ratio Range

AKUS PE Ratio Range Unlock AKUS Revenue

Dividend Yield Range

AKUS Dividend Yield Range Unlock AKUS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AKUS EPS Forecasts Unlock AKUS Revenue
Profile Summary

Akouos Inc. is a precision genetic medicine company. The Company is focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. The Company has developed a precision genetic medicine platform that incorporates a vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV) and a delivery approach. The Company is focused on executing on its strategic initiatives, which include the advancement of its lead product candidate, AK-OTOF, and expansion of its pipeline and development of internal manufacturing capabilities. In addition to this, the Company’s other programs include CLRN1 for Usher Type IIIA and GJB2 for a common form of monogenic deafness and hearing loss.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated November 23, 2016
No. of Shareholders: 22
No. of Employees: 57
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 32,481,704
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AKUS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AKUS
Upcoming Events for AKUS
Frequently Asked Questions for Akouos Inc
What is the Akouos Inc share price?

As of 10/07/20, shares in Akouos Inc are trading at $22.3, giving the company a market capitalisation of £573.4m. This share price information is delayed by 15 minutes.

How has the Akouos Inc share price performed this year?

Shares in Akouos Inc are currently trading at $22.3 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Akouos Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Akouos Inc?

There are no analysts currently covering Akouos Inc.

When will Akouos Inc next release its financial results?

Akouos Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Akouos Inc dividend yield?

Akouos Inc does not currently pay a dividend.

Does Akouos Inc pay a dividend?

Akouos Inc does not currently pay a dividend.

When does Akouos Inc next pay dividends?

Akouos Inc does not currently pay a dividend.

How do I buy Akouos Inc shares?

To buy shares in Akouos Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Akouos Inc?

Shares in Akouos Inc are currently trading at $22.3, giving the company a market capitalisation of £573.4m.

Where are Akouos Inc shares listed? Where are Akouos Inc shares listed?

Here are the trading details for Akouos Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AKUS
What kind of share is Akouos Inc?

Based on an overall assessment of its quality, value and momentum, Akouos Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Akouos Inc share price forecast 2020?

We were not able to load any forecast data for Akouos Inc.

How can I tell whether the Akouos Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akouos Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $22.3, shares in Akouos Inc are trading at 1.73% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Akouos Inc PE Ratio?

We were not able to find PE ratio data for Akouos Inc.

Who are the key directors of Akouos Inc?

Akouos Inc's management team is headed by:

Emmanuel Simons - PRE
Michael Mckenna - CFD
Rabia Ozden - OTH
Gregory Robinson - CSO
Edward Mathers - IND
Kush Parmar - IND
Heather Preston - IND
Saira Ramasastry - IND
Vicki Sato - IND
Who are the major shareholders of Akouos Inc?

Here are the top five shareholders of Akouos Inc based on the size of their shareholding:

New Enterprise Associates (NEA) Venture Capital
Percentage owned: 13.22% (4.29m shares)
Partners Innovation Fund II, L.P. Individual Investor
Percentage owned: 1.16% (377k shares)
Simons (Emmanuel J. Ph.D.) Individual Investor
Percentage owned: 0.73% (237k shares)
Marshfield Advisers LLC Individual Investor
Percentage owned: 0.46% (150k shares)
Lonza Houston, INC. Individual Investor
Percentage owned: 0.37% (119k shares)
Similar to AKUS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.